The Role of Phosphatidylinositol 3-Kinase Signaling Pathways in Pancreatic Cancer

Yao, 2010, Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway, Med Oncol, 27, 1017, 10.1007/s12032-009-9326-5 Lockhart, 2005, Treatment for pancreatic cancer: current therapy and continued progress, Gastroenterology, 128, 1642, 10.1053/j.gastro.2005.03.039 Schneider, 2005, Pancreatic cancer: basic and clinical aspects, Gastroenterology, 128, 1606, 10.1053/j.gastro.2005.04.001 Westphal, 2003, Apoptosis: targets in pancreatic cancer, Mol Cancer, 2, 6, 10.1186/1476-4598-2-6 Parkin, 2001, Cancer burden in the year 2000. The global picture, Eur J Cancer, 37, S4, 10.1016/S0959-8049(01)00267-2 Jemal, 2010, Cancer statistics, 2010, CA Cancer J Clin, 60, 277, 10.3322/caac.20073 Fryer, 2009, Recent advances and developments in treatment strategies against pancreatic cancer, Curr Clin Pharmacol, 4, 102, 10.2174/157488409788185007 Jonckheere, 2009, Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by ap-2α overex-pression, Br J Cancer, 101, 637, 10.1038/sj.bjc.6605190 O'Reilly, 2007, Cytotoxic therapy for advanced pancreatic adenocarcinoma, Semin Oncol, 34, 347, 10.1053/j.seminoncol.2007.05.009 Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368 Schonleben, 2006, Pik3ca mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas, Clin Cancer Res, 12, 3851, 10.1158/1078-0432.CCR-06-0292 Jiao, 2011, DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors, Science, 331, 1199, 10.1126/science.1200609 Zhao, 2008, Class I PI3K in oncogenic cellular transformation, Oncogene, 27, 5486, 10.1038/onc.2008.244 Solomon, 2009, Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer, J Thorac Oncol, 4, 787, 10.1097/JTO.0b013e3181a74dba Kierbel, 2005, The phosphoinositol-3-kinase-protein kinase B/Akt pathway is critical for pseudomonas aeruginosa strain PAK internalization, Mol Biol Cell, 16, 2577, 10.1091/mbc.E04-08-0717 Vanhaesebroeck, 2000, The PI3K-PDK1 connection: more than just a road to PKB, Biochem J, 346, 561, 10.1042/0264-6021:3460561 Cantley, 2002, The phosphoinositide 3-kinase pathway, Science, 296, 1655, 10.1126/science.296.5573.1655 Aikin, 2004, Crosstalk between phosphatidylinositol 3-kinase/ Akt and c-Jun NH2-terminal kinase mediates survival of isolated human islets, Endocrinology, 145, 4522, 10.1210/en.2004-0488 Reichert, 2007, Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells, Cancer Res, 67, 4149, 10.1158/0008-5472.CAN-06-4484 Schild, 2009, PI3K signaling maintains c-Myc expression to regulate transcription of E2F1 in pancreatic cancer cells, Mol Carcinog, 48, 1149, 10.1002/mc.20569 Chaussepied, 2004, Transcriptional regulation of Akt activation by E2F, Mol Cell, 16, 831, 10.1016/j.molcel.2004.11.003 Ladu, 2008, E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/ mTOR and COX-2 in a mouse model of human liver cancer, Gastroenterology, 135, 1322, 10.1053/j.gastro.2008.07.012 Shaw, 2008, Antagonism of E2F-1 regulated BNIP3 transcription by NF-κB is essential for basal cell survival, Proc Natl Acad Sci USA, 105, 20734, 10.1073/pnas.0807735105 Diehl, 1998, Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization, Genes Dev, 12, 3499, 10.1101/gad.12.22.3499 Cohen, 2001, The renaissance of GSK3, Nat Rev Mol Cell Biol, 2, 769, 10.1038/35096075 Bader, 2005, Oncogenic PI3K deregulates transcription and translation, Nat Rev Cancer, 5, 921, 10.1038/nrc1753 Steelman, 2008, Akt as a therapeutic target in cancer, Expert Opin Ther Targets, 12, 1139, 10.1517/14728222.12.9.1139 Zacharek, 2005, Negative regulation of TSC1-TSC2 by mammalian D-type cyclins, Cancer Res, 65, 11354, 10.1158/0008-5472.CAN-05-2236 Zhang, 2003, Loss of TSC1/ TSC2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR, J Clin Invest, 112, 1223, 10.1172/JCI200317222 Zhang, 2007, PDGFRs are critical for PI3K/ Akt activation and negatively regulated by mTOR, J Clin Invest, 117, 730, 10.1172/JCI28984 Harrington, 2004, The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins, J Cell Biol, 166, 213, 10.1083/jcb.200403069 Shah, 2004, Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies, Curr Biol, 14, 1650, 10.1016/j.cub.2004.08.026 Ma, 2005, Genetic analysis of PTEN and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression, Genes Dev, 19, 1779, 10.1101/gad.1314405 Missiaglia, 2010, Pancreatic endocrine tumors: expression profiling evidences a role for Akt-mTOR pathway, J Clin Oncol, 28, 245, 10.1200/JCO.2008.21.5988 Asano, 2005, Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells, Cancer Res, 65, 9164, 10.1158/0008-5472.CAN-05-0779 Tomizawa, 2010, Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer, World J Gastroenterol, 16, 1854, 10.3748/wjg.v16.i15.1854 Shirk, 2005, Epidermal growth factor mediates detachment from and invasion through collagen I and matrigel in capan-1 pancreatic cancer cells, BMC Gastroenterol, 5, 12, 10.1186/1471-230X-5-12 Xu, 2010, Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells, BMC Cancer, 10, 161, 10.1186/1471-2407-10-161 O'Reilly, 2006, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt, Cancer Res, 66, 1500, 10.1158/0008-5472.CAN-05-2925 Johnson, 2009, Insulin-like growth factor binding protein-5 influences pancreatic cancer cell growth, World J Gastroenterol, 15, 3355, 10.3748/wjg.15.3355 Agbunag, 2004, Oncogenic K-Ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells, Cancer Res, 64, 5659, 10.1158/0008-5472.CAN-04-0807 Guertin, 2006, Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1, Dev Cell, 11, 859, 10.1016/j.devcel.2006.10.007 Easton, 2006, Irs-1: auditing the effectiveness of mTOR inhibitors, Cancer Cell, 9, 153, 10.1016/j.ccr.2006.02.027 Thimmaiah, 2003, Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling pathways, Cancer Res, 63, 364 Buck, 2006, Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors, Mol Cancer Ther, 5, 2676, 10.1158/1535-7163.MCT-06-0166 Javle, 2010, Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies, BMC Cancer, 10, 368, 10.1186/1471-2407-10-368 Hsu, 2008, Cancer cell metabolism: Warburg and beyond, Cell, 134, 703, 10.1016/j.cell.2008.08.021 Kim, 2010, Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations, Radiology, 257, 87, 10.1148/radiol.10100015 Melstrom, 2008, Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/ Akt pathway in human pancreatic cancer cells, Pancreas, 37, 426, 10.1097/MPA.0b013e3181735ccb Sanchez, 2001, The inhibition of phosphatidylinositol-3-kinase induces neurite retraction and activates GSK3, J Neurochem, 78, 468, 10.1046/j.1471-4159.2001.00453.x Zhang, 2011, Stem cell factor/c-kit signaling enhances invasion of pancreatic cancer cells via HIF-lα under normoxic condition, Cancer Lett, 303, 108, 10.1016/j.canlet.2011.01.017 Walter, 2009, Serum fatty acid synthase as a marker of pancreatic neoplasia, Cancer Epidemiol Biomarkers Prev, 18, 2380, 10.1158/1055-9965.EPI-09-0144 Wang, 2005, Positive feedback regulation between Akt activation and fatty acid synthase expression in ovarian carcinoma cells, Oncogene, 24, 3574, 10.1038/sj.onc.1208463 Edderkaoui, 2011, NADPH oxidase activation in pancreatic cancer cells is mediated through Akt-dependent up-regulation of p22phox, J Biol Chem, 286, 7779, 10.1074/jbc.M110.200063 Gerwins, 2000, Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis, Crit Rev Oncol Hematol, 34, 185, 10.1016/S1040-8428(00)00062-7 Ma, 2009, PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells, Mol Cell Biochem, 331, 161, 10.1007/s11010-009-0154-x Jiang, 2000, Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells, Proc Natl Acad Sci USA, 97, 1749, 10.1073/pnas.040560897 Laklai, 2009, Thrombospondin-1 is a critical effector of oncosuppressive activity of sst 2 somatostatin receptor on pancreatic cancer, Proc Natl Acad Sci USA, 106, 17769, 10.1073/pnas.0908674106 Delesque, 1997, sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells, Cancer Res, 57, 956 Summy, 2005, c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK, Pancreas, 31, 263, 10.1097/01.mpa.0000178280.50534.0c Xiong, 2004, Molecular targeting therapy for pancreatic cancer, Cancer Chemother Pharmacol, 54, S69 Asano, 2004, The PI 3-kinase/Akt signaling pathway is activated due to aberrant PTEN expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells, Oncogene, 23, 8571, 10.1038/sj.onc.1207902 Stoll, 2005, Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer, Gut, 54, 109, 10.1136/gut.2004.046706 Perugini, 2000, Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent, J Surg Res, 90, 39, 10.1006/jsre.2000.5833 Ng, 2000, Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells, Cancer Res, 60, 5451 Semba, 2003, Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas, Pancreas, 26, 250, 10.1097/00006676-200304000-00008 Takeda, 2004, Role of the phosphatidylinositol 3′-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines, Pancreas, 28, 353, 10.1097/00006676-200404000-00026 Chen, 2008, Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NFKB-dependent pathway, J Immunol, 181, 8441, 10.4049/jimmunol.181.12.8441 Datta, 1997, Akt phosphorylation of bad couples survival signals to the cell-intrinsic death machinery, Cell, 91, 231, 10.1016/S0092-8674(00)80405-5 Yamada, 1991, Species-specific differences in heterogonic development of serially transferred free-living generations of strongyloides planiceps and strongyloides stercoralis, J Parasitol, 77, 592, 10.2307/3283165 Kauffmann-Zeh, 1997, Suppression of c-Myc-induced apoptosis by RAS signalling through PI(3)K and PKB, Nature, 385, 544, 10.1038/385544a0 Ng, 2001, Wortmannin inhibits PKB/Akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice, Clin Cancer Res, 7, 3269 Fahy, 2003, Akt inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2, Br J Cancer, 89, 391, 10.1038/sj.bjc.6601037 Fahy, 2004, Inhibition of Akt abrogates chemotherapy-induced NFκB survival mechanisms: implications for therapy in pancreatic cancer, J Am Coll Surg, 198, 591, 10.1016/j.jamcollsurg.2003.12.005 Bondar, 2002, Inhibition of the phosphatidylinositol 3'-kinase-Akt pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo, Mol Cancer Ther, 1, 989 Binker, 2009, EGF promotes invasion by PANC-1 cells through Rac1/ROS-dependent secretion and activation of MMP-2, Biochem Biophys Res Commun, 379, 445, 10.1016/j.bbrc.2008.12.080 Dise, 2008, Epidermal growth factor stimulates Rac activation through Src and phosphatidylinositol 3-kinase to promote colonic epithelial cell migration, Am J Physiol Gastrointest Liver Physiol, 294, G276, 10.1152/ajpgi.00340.2007 Ellenrieder, 2000, Role of MT-MMPs and MMP-2 in pancreatic cancer progression, Int J Cancer, 85, 14, 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.0.CO;2-O Binker, 2010, Hypoxia-reoxygenation increase invasiveness of PANC-1 cells through Rac1/MMP-2, Biochem Biophys Res Commun, 393, 371, 10.1016/j.bbrc.2010.01.125 Liau, 2006, HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma, Cancer Res, 66, 11613, 10.1158/0008-5472.CAN-06-1460 Ma, 2010, IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/ PI3K/Akt signaling pathway in pancreatic cancer cells, J Surg Res, 160, 90, 10.1016/j.jss.2008.08.016 Teranishi, 2009, Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo, Cancer Sci, 100, 770, 10.1111/j.1349-7006.2009.01084.x Kim, 2010, TM-PRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin α5 and its signaling pathways, Carcinogenesis, 31, 597, 10.1093/carcin/bgq024 Xia, 2010, Effect of anti-cancer drugs on the expression of BIC/miR-155 in human pancreatic cancer PANC-1 cells (in Chinese), Zhonghua Yi Xue ZaZhi, 90, 123 Fujiwara, 2008, Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells, J Exp Clin Cancer Res, 27, 76, 10.1186/1756-9966-27-76 Liu, 2007, siRNA directed against TRKA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway, Oncol Rep, 18, 673 Maira, 2009, PI3K inhibitors for cancer treatment: where do we stand?, Biochem Soc Trans, 37, 265, 10.1042/BST0370265 Ihle, 2004, Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling, Mol Cancer Ther, 3, 763, 10.1158/1535-7163.763.3.7 Garlich, 2008, A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity, Cancer Res, 68, 206, 10.1158/0008-5472.CAN-07-0669 Knight, 2006, A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling, Cell, 125, 733, 10.1016/j.cell.2006.03.035 Knight, 2007, Chemically targeting the PI3K family, Biochem Soc Trans, 35, 245, 10.1042/BST0350245 Edling, 2010, Key role of phosphoinositide 3-kinase class Ib in pancreatic cancer, Clin Cancer Res, 16, 4928, 10.1158/1078-0432.CCR-10-1210 Maira, 2008, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity, Mol Cancer Ther, 7, 1851, 10.1158/1535-7163.MCT-08-0017 Cao, 2009, Activity of a novel, dual PI3-kinase/ mTOR inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts, Br J Cancer, 100, 1267, 10.1038/sj.bjc.6604995 Berna, 2009, Gastrointestinal growth factors and hormones have divergent effects on Akt activation, Cell Signal, 21, 622, 10.1016/j.cellsig.2009.01.003 Zhou, 2008, Phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway is critical for survival and proliferation of pancreatic cancer stem-like side population cells (in Chinese), Zhonghua Yi Xue Za Zhi, 88, 2994